ENDPOINTS

Lykos’ interim CEO is set to step down

Lykos Therapeutics’ interim CEO Michael Mullette is planning to step down, according to a source familiar with the decision. Mullette relayed the move to staff in February, saying that he would stay on through a ...

Mar 28, 2025 - 21:03
 0
Lykos’ interim CEO is set to step down
Lykos Therapeutics’ interim CEO Michael Mullette is planning to step down, according to a source familiar with the decision. Mullette relayed the move to staff in February, saying that he would stay on through a ...
Read More

Tags:

Previous Article

'Chappie' is 10 years old, and Blomkamp's flawed humanist take on robots and AI ...

Next Article

COVID research cuts target work on antivirals and vaccines to prevent future pan...

Related Posts

Biogen gets $250M in Royalty Pharma deal for lupus program

Biogen gets $250M in Royalty Pharma deal for lupus program

Feb 12, 2025  0

Federal Circuit ruling keeps Amgen's Eylea biosimilar on the market

Federal Circuit ruling keeps Amgen's Eylea biosimilar o...

Mar 14, 2025  0

Bipartisan 'pill penalty' fix and other bills vie for inclusion in reconciliation package

Bipartisan 'pill penalty' fix and other bills vie for i...

Feb 28, 2025  0